+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 38 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.

Age: 18Years +All GendersPhase 3
210 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combination of two investigational drugs, avutometinib and defactinib, compared to standard treatments chosen by doctors in patients with recurrent low-grade serous ovarian cancer LGSOC who have progressed after prior platinum-based therapy. This Phase 3, international, randomized, open-label study aims to compare progression-free survival and also assess overall survival, safety, quality of life, and disease symptoms. The study is conducted by specialists in gynecological cancer. Participants will receive either the combination of avutometinib and defactinib or one of four standard treatments recommended for recurrent LGSOC. Avutometinib is given orally at 3.2 mg twice weekly for 21 days followed by 7 days off in a 28-day cycle, combined with defactinib given orally at 200 mg twice daily on the same schedule. The standard treatments include pegylated liposomal doxorubicin, paclitaxel, anastrozole, or letrozole, each administered according to their usual dosing schedules. Patients initially receiving standard treatment who experience disease progression may switch to the investigational drug combination. During the study, participants will have regular visits for treatment and follow-up assessments including laboratory tests and evaluations of tumor status. Researchers will monitor progression-free survival for up to 24 months and overall survival for up to 5 years. They will also assess response rates, duration of response, disease control, adverse events, blood drug levels, and quality of life using questionnaires. The total study duration may extend until 2031, with ongoing monitoring of health and symptoms throughout.

Age: 18Years +FEMALEPhase 3
105 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, how the body processes and reacts to the drug BG-75098, and its preliminary ability to fight tumors in adults with advanced solid tumors. The study includes two phases Phase 1a dose escalation and Phase 1b dose expansion. It aims to understand BG-75098 alone and combined with BGB-43395 and fulvestrant in treating these cancers. Participants will receive BG-75098 orally either alone or combined with BGB-43395 also oral and fulvestrant given by intramuscular injection. The study first tests increasing doses of BG-75098 alone and with the other drugs to find the recommended dose. Then, participants receive the recommended doses either as monotherapy or combination therapy, depending on the group. During the study, participants are monitored for side effects, drug levels in the blood, and tumor response. Assessments include tracking adverse events up to 30 days after the last dose and up to 2 years, measuring how long the response lasts, time to response, and disease progression. Blood samples are taken at specific times between treatment cycles to analyze drug concentration and behavior. Overall participation can last up to two years with regular evaluations.

Age: 18Years +All GendersPhase 1
23 locations
G

Actively Recruiting

Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.

Age: 18Years +All GendersPhase 3
415 locations
S

Actively Recruiting

Researchers are studying vobramitamab tavatecan MGC026 to understand its safety, tolerability, how the body processes it, immune response, and early signs of cancer-fighting activity in adults with relapsed or refractory, unresectable, locally advanced, or metastatic solid tumors. This phase 1 trial includes a dose escalation phase and a cohort expansion phase, with an additional module combining MGC026 with pembrolizumab to assess combination therapy effects. Participants receive vobramitamab tavatecan through intravenous infusion every three weeks, with the dose assigned at enrollment. In the combination phase, pembrolizumab is given at 200 mg intravenously every three weeks. Participants may receive up to 35 treatment cycles, provided there are no severe side effects and the cancer does not worsen. The study includes different cohorts and dose levels to explore optimal dosing and combination strategies. During the study, participants are closely monitored for side effects and cancer progression. Blood samples are collected for routine lab work and research, including measuring drug levels and immune responses. Tumor samples may also be collected for research. The primary outcome measures focus on safety and adverse events over up to 135 weeks, while secondary outcomes assess response rates and duration. The study is expected to continue until April 2029, with ongoing evaluations throughout the treatment period.

Age: 18Years +All GendersPhase 1
12 locations
E

Actively Recruiting

Researchers are evaluating risvutatug rezetecan Ris-Rez in men with metastatic castration-resistant prostate cancer mCRPC to see how well it works compared to the best supportive or standard care, which may include hormone therapy with androgen receptor pathway inhibitors ARPI. The study aims to determine if Ris-Rez can shrink or eliminate tumors, improve survival, and enhance quality of life. It also assesses the safety and tolerability of Ris-Rez and seeks to better understand its side effects. Participants are randomly assigned to receive either Ris-Rez or physicians choice of best supportivestandard care, which may include ARPI drugs such as Enzalutamide or Abiraterone combined with Prednisone or Prednisolone. The study is conducted in a parallel design and monitors participants over a period of up to approximately 169 weeks to evaluate treatment effects. During the study, participants undergo regular assessments including radiographic scans to measure disease progression and survival, evaluations of pain progression, tumor response, prostate-specific antigen levels, and skeletal events. Safety is closely monitored by tracking adverse events and immune responses to Ris-Rez. Participants experiences with the study treatment are also collected. The total participation may last over three years, with ongoing evaluations throughout this time.

Age: 18Years +MALEPhase 3
6 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effects of ROC-101 in adults diagnosed with Pulmonary Arterial Hypertension PAH or Pulmonary Hypertension associated with Interstitial Lung Disease ILD-PH. This Phase 2a, open-label, single-arm exploratory study includes participants classified under World Health Organization WHO Group I PAH or Group III ILD-PH, aiming to assess oral doses of ROC-101 alongside standard care. Participants will receive oral ROC-101 daily, starting at 10 mg and gradually increasing to 40 mg for a 24-week treatment period, combined with standard of care therapy. After this period, participants may continue in a long-term extension phase until the study program concludes or regulatory approval is granted. Evaluations include hemodynamic measurements obtained through right heart catheterization and monitoring of adverse events. Throughout the study, participants will undergo assessments such as pulmonary function tests, exercise capacity tests 6-minute walk distance, and right heart catheterization measurements at baseline and 24 weeks. Researchers will track changes in pulmonary vascular resistance and safety outcomes, along with various cardiac and respiratory function parameters. The total study duration includes the initial 24-week treatment phase followed by an optional long-term extension period for continued monitoring.

Age: 18Years - 80YearsAll GendersPhase 2
24 locations
P

Actively Recruiting

This research aims to compare overall survival in men with chemotherapy-naefve metastatic castration-resistant prostate cancer. The study evaluates the combination of xaluritamig and abiraterone against the investigators choice of treatments, which include abiraterone, docetaxel, or cabazitaxel. The trial is a phase 3, open-label, randomized study sponsored by Amgen. Participants will be randomly assigned to receive either xaluritamig administered intravenously combined with oral abiraterone acetate, or the investigators choice of one of the following treatments daily oral abiraterone acetate, or intravenous docetaxel or cabazitaxel given every three weeks. Treatments continue with regular monitoring throughout the study period, which lasts up to approximately 51 months for outcome assessments. Participants will undergo various assessments including imaging scans such as CT, MRI, or bone scans to confirm metastatic disease and monitor progression. Researchers will also evaluate pain levels, quality of life, prostate-specific antigen PSA responses, and adverse events throughout the study. Follow-up evaluations will continue for up to 51 months to measure survival and other health outcomes, with safety monitoring conducted throughout the participation period.

Age: 18Years +MALEPhase 3
159 locations
E

Actively Recruiting

Researchers are evaluating the safety and changes in disease activity of different treatment combinations using mirvetuximab soravtansine with carboplatin, bevacizumab, or bevacizumab alone in adult women with ovarian cancer. This phase 2 study focuses on participants confirmed to have folate receptor alpha positive tumors through a specific assay. The purpose is to assess adverse events and treatment responses across multiple treatment groups. Participants will be assigned to one of three substudies, each with different treatment arms. Treatments involve intravenous infusions of mirvetuximab soravtansine combined with bevacizumab, carboplatin, or both, with dosing variations and sequences depending on the substudy. The study duration varies from approximately 31 to 40 months based on the treatment group and includes follow-up after initial combination therapies. During the study, participants will attend regular hospital or clinic visits for medical assessments including blood tests and scans. Researchers will monitor treatment-emergent adverse events, ocular adverse events, peripheral neuropathy, lung disease, and overall and progression-free survival using standardized criteria. The safety and effectiveness of the treatments will be tracked over the entire study period, which may require a higher treatment burden than standard care.

Age: 18Years +FEMALEPhase 2
86 locations
C

Actively Recruiting

Researchers are studying an experimental drug called odronextamab combined with chemotherapy in patients with Diffuse Large B-cell Lymphoma DLBCL. This includes adults with untreated DLBCL as well as those whose disease has returned or not responded to treatment. The study aims to evaluate the safety, dosing, and effectiveness of odronextamab plus chemotherapy compared to the current standard treatment, rituximab combined with chemotherapy. The study is divided into Part 1A and 1B, which focus on determining safe doses and schedules of odronextamab combined with chemotherapy drugs including cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone. Part 2 is a randomized comparison where participants receive either odronextamab plus chemotherapy or rituximab plus chemotherapy. Odronextamab and rituximab are given by intravenous infusion, with rituximab also possibly given subcutaneously. Participants will be monitored for side effects, disease progression, and quality of life over time. Assessments include measuring drug levels in the blood, immune response to the drug, and physical functioning questionnaires. The study will follow participants for up to five years to evaluate progression-free survival and other outcomes. Safety and adverse events will be tracked for up to two years.

Age: 18Years +All GendersPhase 3
195 locations

1-10 of 38

1